November 29, 2016 04:33 PM EST
R&D

Hot on the heels of a clin­i­cal hold, Ar­row­head torch­es its clin­i­cal pipeline, slash­es staff

John Carroll

Editor & Founder

Just three weeks af­ter Ar­row­head Phar­ma­ceu­ti­cals $AR­WR was forced to put its lead pro­gram on clin­i­cal hold, the biotech is torch­ing every­thing re­lat­ed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A look at biotech's year of the megaround

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Re­gen­eron buys Lon­don-based oc­u­lar biotech

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times